ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 171 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2019. The put-call ratio across all filers is 0.91 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $8,372,000 | -5.0% | 131,846 | +3.7% | 0.39% | -11.3% |
| Q1 2019 | $8,814,000 | +53.0% | 127,081 | -4.1% | 0.44% | +30.3% |
| Q4 2018 | $5,760,000 | -42.2% | 132,466 | +1.5% | 0.34% | -22.9% |
| Q3 2018 | $9,967,000 | -1.3% | 130,563 | -0.6% | 0.44% | -15.0% |
| Q2 2018 | $10,099,000 | +56.9% | 131,379 | +4.1% | 0.52% | +43.4% |
| Q1 2018 | $6,436,000 | +12.6% | 126,230 | +2.5% | 0.36% | +9.4% |
| Q4 2017 | $5,714,000 | -6.1% | 123,191 | +7.8% | 0.33% | -14.5% |
| Q3 2017 | $6,087,000 | -12.7% | 114,294 | +1.8% | 0.39% | -19.5% |
| Q2 2017 | $6,975,000 | -6.1% | 112,296 | +2.4% | 0.48% | -13.8% |
| Q1 2017 | $7,431,000 | -33.3% | 109,629 | -30.8% | 0.56% | -42.4% |
| Q4 2016 | $11,136,000 | +42.3% | 158,390 | +43.6% | 0.97% | +20.8% |
| Q3 2016 | $7,824,000 | – | 110,291 | – | 0.80% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |